ライフサイエンスコーパス: febrile

1 Most experienced respiratory (81%) or febrile (64%) illness before limb weakness onset.

2 Children aged </= 15 years and febrile adults were also tested for malaria by rapid dia

3 No participant became febrile after MVA-BN-Filo, compared with 3 of 60 partici

4 Newly febrile and asymptomatic infections in Malians were stat

5 ildren assessed (97.3% [15 495/15 932]) were febrile and most febrile cases (82.1% [12 725/15 495]) t

6 Four individuals presented with febrile and multiple afebrile, often focal seizure types

7 disability with delayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, s

8 1,691 were enrolled; of these 566 (34%) were febrile, and 1,125 (66%) were afebrile.

9 flammatory marker levels were compared among febrile aseptic, bacterial, and nonmeningitis patients t

10 including aphthae, gastrointestinal disease, febrile attacks, and small-vessel vasculitis characteris

11 Animals became febrile between days 5 and 6, maintaining a high fever b

12 septic shock, 207 of 378 (55%; 50-60%) were febrile by history or measurement.

13 97.3% [15 495/15 932]) were febrile and most febrile cases (82.1% [12 725/15 495]) tested were RDT po

14 Of all febrile cases in the study, DENV-positive C cases accoun

15 Among febrile children </=5 years of age, UMT sensitivity was

16 Febrile children account for 15% of emergency department

17 cterize dengue virus (DENV) infections among febrile children enrolled in a pediatric cohort study wh

18 Management of febrile children is an intrinsic aspect of pediatric pra

19 the e-POCT tool was non-inferior to that of febrile children managed by a validated electronic algor

20 to determine whether the clinical outcome of febrile children managed by the e-POCT tool was non-infe

21 Febrile children presenting to participating hospitals i

22 urkina Faso, Nigeria, and Uganda to diagnose febrile children using malaria rapid diagnostic tests, a

23 In febrile children, clinicians should not delay testing fo

24 riminating bacterial from viral infection in febrile children.

25 12.40 pg/ml, P < 0.001) when compared to the febrile control group.

26 30 days after vaccination, mainly pneumonia, febrile convulsions, and salmonella sepsis.

27 Among febrile critically ill adults, treatment with acetaminop

28 mperature, blood pressure, and heart rate in febrile critically ill patients.

29 There was no significant difference in febrile disease among influenza-infected employees who h

30 ratyphi A, is the leading cause of bacterial febrile disease in South Asia.

31 s (ZIKV) is causing an explosive outbreak of febrile disease in the Americas.

32 ith infected animals, are characterized by a febrile disease that sometimes leads to encephalitis or

33 (CHIKV), a mosquito-borne alphavirus, causes febrile disease, muscle and joint pain, which can become

34 members of the Arenaviridae can cause acute febrile diseases in humans, often resulting in lethality

35 hat recently emerged as a causative agent of febrile encephalitis and severe respiratory disease in h

36 ged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resol

37 A subset of patients with recurrent febrile episodes and systemic inflammation of unknown or

38 Approximately 10% of the febrile episodes in each cohort were confirmed to be VCD

39 Acute febrile episodes were determined to be VCD by means of a

40 aracts, severe psychomotor regression during febrile episodes, epilepsy, neutropenia with frequent in

41 Over 19 months, 54 013 children had 102 504 febrile episodes, of which 32% (31 817 episodes) had sym

42 ferral episodes were almost one-third of all febrile episodes.

43 We included febrile (>/=38 degrees C), previously healthy, full-term

44 s (HCWs) to patients, many hospitals exclude febrile HCWs from working, but allow afebrile HCWs with

45 Patients were grouped as febrile if they had a subjective fever or a measured tem

46 Acute febrile illness (AFI) is associated with substantial mor

47 S1) and anti-DENV IgM during suspected acute febrile illness (AFI) outbreaks in four countries.

48 nts who presented at the hospital with a non-febrile illness (control group 1; n=98) and age-matched

49 splant recipient who presented with an acute febrile illness 1 year after transplantation with a rapi

50 osquitoes, CHIKV is responsible for an acute febrile illness accompanied by several characteristic sy

51 been extensively studied as a cause of acute febrile illness and an emerging tick-borne zoonosis in t

52 romising for differential diagnosis of acute febrile illness and identification of coinfections, alth

53 easingly recognized as an important cause of febrile illness and mortality in sub-Saharan Africa.

54 is a reemerging alphavirus that causes acute febrile illness and severe joint pain in humans.

55 help improve interpretation of the burden of febrile illness and shape policy on fever case managemen

56 We monitored acute febrile illness and virologically confirmed dengue (VCD)

57 Live vaccine reduced febrile illness by 72% (95% CI, 20%-90%).

58 Dengue is an acute febrile illness caused by dengue virus (DENV) and a majo

59 en leads to infectious mononucleosis (IM), a febrile illness characterized by anti-EBV IgM antibody p

60 om 2892 children who presented with an acute febrile illness clinically attributed to a non-DENV caus

61 Kawasaki Disease (KD) is a rare acute febrile illness due to multi-organ vasculitis.

62 ike illness (ILI), diarrhea, and nonspecific febrile illness during 2008 from a population-based surv

63 dardised surveillance of blood culture-based febrile illness in 13 African sentinel sites with previo

64 an genotype ZIKAV caused an outbreak of mild febrile illness in 2007 in Yap State, Federated States o

65 grated program of diagnosis and treatment of febrile illness in 3 African countries.

66 Households with recent febrile illness in a young child in previous 2 weeks wer

67 sponsible for sporadic outbreaks of mild and febrile illness in Africa and Asia, reemerged in the las

68 phi), and leptospirosis are common causes of febrile illness in Asia; meningitis and meningoencephali

69 causes episodic outbreaks of a debilitating febrile illness in humans in countries of South and Cent

70 as a heretofore unrecognized cause of acute febrile illness in humans in Nicaragua and demonstrated

71 of 250,1.2%), the agent of eschar-associated febrile illness in humans.

72 esistant infection among patients with acute febrile illness in India.

73 sease are major causes of invasive bacterial febrile illness in the sampled locations, most commonly

74 leading cause of treatable undifferentiated febrile illness in tropical Asia, caused by the obligate

75 es, DENV-3 PGMK30FRhL3, which produced acute febrile illness in vaccine recipients, and DENV-2 PDK53,

76 ciated with infectious mononucleosis (IM), a febrile illness in which patients have high circulating

77 All had a prodromal febrile illness preceding neurological symptoms by a med

78 ness at the time the patient is experiencing febrile illness that leads to IFN-gamma unresponsiveness

79 ldren aged 2-59 months presenting with acute febrile illness to 9 outpatient clinics in Dar es Salaam

80 ute lower respiratory tract illness or acute febrile illness to a designated outpatient facility in e

81 Human disease ranges from mild febrile illness to severe fatal neurologic infection.

82 f adults and children hospitalized for acute febrile illness was conducted between August 2013 and De

83 ed particularly in patients with nonspecific febrile illness who are immunocompromised or who may hav

84 As most cases present with nonspecific febrile illness with no laboratory-confirmed etiology, e

85 be the case of an expectant mother who had a febrile illness with rash at the end of the first trimes

86 i and Aedes albopictus mosquitoes and causes febrile illness with severe arthralgia in humans.

87 Among 1524 patients hospitalized with acute febrile illness, 133 isolates were found among 115 patie

88 gens that cause an undifferentiated systemic febrile illness, including infections with two common ar

89 tivity by pathogens associated with non-EBOV febrile illness, including malaria parasites.

90 rus that has caused a widespread outbreak of febrile illness, is associated with neurological disease

91 IMPORTANCE Dengue virus (DENV), which causes febrile illness, is transmitted by mosquito vectors thro

92 transplant recipients who present with acute febrile illness, systemic symptoms, lymphadenopathies, a

93 and Southeast Asia and a rare cause of acute febrile illness, Zika virus (ZIKAV) arose from obscurity

94 ers returning from this region with an acute febrile illness.

95 ion on private household costs for childhood febrile illness.

96 imarily associated with invasive disease and febrile illness.

97 othelial parameters between dengue and other febrile illness.

98 25 outpatients (27%) were diagnosed as other febrile illness.

99 of the genus Flavivirus and can cause severe febrile illness.

100 VFV infection mainly include a self-limiting febrile illness.

101 to potential coinfection with a non-malarial febrile illness.

102 Acute undifferentiated febrile illnesses (AFIs) represent a significant health

103 non-DHF group (n = 63) and those with other febrile illnesses (n = 25) (P = .01).

104 ans in this region should aggressively treat febrile illnesses and sepsis with doxycycline for suspec

105 clinically invasive Salmonella disease from febrile illnesses caused by other pathogens.

106 respiratory infections, severe diarrhea and febrile illnesses of unknown origin have all been report

107 Patients with febrile illnesses presenting to an Ebola treatment unit

108 blished through regular household surveys of febrile illnesses recording symptoms eligible for preref

109 For example, malaria and dengue fever are febrile illnesses transmitted through mosquito bites, an

110 mprove the clinical outcome of children with febrile illnesses while reducing antibiotic use through

111 atory parameters comparing dengue with other febrile illnesses.

112 characterized samples from an additional 135 febrile individuals from Thailand were also used.

113 the United States, using samples from 1,021 febrile individuals.

114 Of 1883 febrile infants (median age, 37 days; 55.7% boys), RNA b

115 onal study involving a convenience sample of febrile infants 60 days or younger evaluated for fever (

116 mmonly used or optimal thresholds identified febrile infants 60 days or younger with IBIs with high a

117 NA biosignatures were defined to distinguish febrile infants aged 60 days or younger with vs without

118 sts perform similarly for identifying SBI in febrile infants aged 7 to 91 days.

119 Studies from 1979 to 2015 examining febrile infants and children were included in this revie

120 Young febrile infants are at substantial risk of serious bacte

121 lied to define RNA biosignatures to classify febrile infants by infection type.

122 stic tools are needed to risk stratify young febrile infants for IBIs.

123 Clinicians often risk stratify young febrile infants for invasive bacterial infections (IBIs)

124 y tract infections still remain a concern in febrile infants of all ages.

125 es compared with cultures for discriminating febrile infants with and without bacterial infections an

126 lete blood cell count parameters to identify febrile infants with IBIs.

127 Management of febrile infants younger than 90 days has evolved conside

128 uito-transmitted RNA virus that causes acute febrile infection associated with polyarthralgia in huma

129 ation in infancy or childhood, preceded by a febrile infection, and most patients had repeated episod

130 This has three phases: episode of simple febrile infection, followed by acute refractory seizures

131 Febrile infection-related epilepsy syndrome (FIRES) is a

132 The term 'Febrile infection-related epilepsy syndrome' (FIRES) has

133 across the globe with the newly coined term 'Febrile infection-related epilepsy syndrome'(FIRES) for

134 Thirty children with an acute febrile infectious disease and 30 healthy children were

135 tted fever is a rare acute and multisystemic febrile infectious disease with a mortality rate of >/=5

136 Immunisation reduced maternal febrile influenza-like illness with an overall efficacy

137 with Streptococcus species and age of first febrile lower respiratory illness, both of which are kno

138 Ebola virus disease, to prevent the onset of febrile malaria and subsequent admission to ETUs.

139 vels of 9G4(+) IgG increased following acute febrile malaria but did not increase with age as humoral

140 ulticlonal infections are at reduced risk of febrile malaria during follow-up.

141 gh the dry season and the subsequent risk of febrile malaria in 225 individuals aged 2-25 years in Ma

142 es previously shown to be protective against febrile malaria in this same cohort were significantly a

143 ore the rainy season were at reduced risk of febrile malaria, compared with individuals who were unin

144 contribute to protection against subsequent febrile malaria, possibly by maintaining protective immu

145 thout conferring enhanced protection against febrile malaria.

146 .30-.73; P = .0008) with protection against febrile malaria.

147 ntigens were associated with protection from febrile malaria.

148 95% CI = .34-.84; Pcorrected = .03) against febrile malaria.

149 All 28 patients developed non-specific febrile manifestations, including fever in 23 (82%), hea

150 was first detected in 1947 in the blood of a febrile monkey in Uganda's Zika Forest and in crushed su

151 ults who were either asymptomatic (n = 5) or febrile (n = 3) during their first seasonal PCR-positive

152 There were 29 episodes of febrile neutropenia (10%).

153 adverse events included fatigue (13.1%) and febrile neutropenia (11.5%).

154 (24 [29%] vs 5 [12%]), but not grade 3 or 4 febrile neutropenia (12 [14%] vs 7 [18%]).

155 33%, and 39%), fatigue (13%, 30%, and 20%), febrile neutropenia (13%, 17%, and 6.1%), and anemia (6.

156 (32%), anemia (30%), thrombocytopenia (24%), febrile neutropenia (14%), mucositis (11%), and rash (5%

157 8 [3%]), bone pain (16 [5%] vs 5 [2%]), and febrile neutropenia (16 [5%] vs 9 [3%]).

158 n the placebo plus cytarabine group included febrile neutropenia (167 [47%] vs 117 [33%]), neutropeni

159 m (63.6% v 50.9%) including a higher rate of febrile neutropenia (21.4% v 12.6%).

160 [7%]), neutropenia (31 [17%] vs seven [8%]), febrile neutropenia (22 [12%] vs ten [11%]), and pneumon

161 he most common grade 3-4 adverse events were febrile neutropenia (23 [15%] of 152 in the aprepitant g

162 The most common serious adverse event was febrile neutropenia (23 [15%] patients in the aprepitant

163 nts who received gemcitabine and docetaxel), febrile neutropenia (26 [20%] and 15 [12%]), fatigue (ei

164 ll 285 serious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse eve

165 day and 10-day schedules, respectively, were febrile neutropenia (27 [53%] vs 25 [48%]), pneumonia (1

166 The most common serious adverse events were febrile neutropenia (29 [31%] of 93 patients), pneumonia

167 egardless of relationship to treatment, were febrile neutropenia (31 [61%] of 51 patients on the 5-da

168 zumab), diarrhoea (33 [15%] vs 2 [<1%]), and febrile neutropenia (33 [15%] vs 0).

169 common grade 3 or higher adverse events were febrile neutropenia (38 [41%] of 93 patients), pneumonia

170 iarrhea (7%), nausea (7%), fatigue (6%), and febrile neutropenia (4%).

171 The most frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (31%).

172 neutropenia (124 [60%] of 207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo g

173 requent grade 3 or worse adverse events were febrile neutropenia (48 patients, 25%), neutropenia (30

174 group), neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia (57 [18%] vs 34 [11%]), leucopenia (

175 ] for lenalidomide vs 85 [16%] for placebo), febrile neutropenia (62 [12%] vs 23 [4%]), diarrhoea (37

176 s irrespective of relation to treatment were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]

177 nts occurring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to tr

178 ous adverse events were pyrexia (six [12%]), febrile neutropenia (five [10%]), lower respiratory trac

179 ), neutropenia (10 [31%] vs four [11%]), and febrile neutropenia (five [16%] vs none).

180 ), pneumonia (five [5%] and five [11%]), and febrile neutropenia (five [5%] and six [13%]).

181 (seven [7%] each), pneumonia (six [6%]), and febrile neutropenia (five [5%]).

182 han one patient) serious adverse events were febrile neutropenia (four [1%] vs one [<1%]) and neutrop

183 y group compared with pneumonia (four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), a

184 vs 28 [6%]; grade 4, 98 [20%] vs 77 [15%]), febrile neutropenia (grade 3, 52 [10%] vs 31 [6%]; grade

185 : 40 [37%] of 108; group D: 60 [64%] of 94), febrile neutropenia (group A: 10 [9%]; group B: 12 [11%]

186 de 3 to 4 nonhematologic toxicities included febrile neutropenia (n = 7) and infection (n = 4).

187 ing FOLFIRINOX alone were neutropenia (n=6), febrile neutropenia (n=1), anaemia (n=2), lymphopenia (n

188 evere adverse events in nine patients due to febrile neutropenia (n=4), diarrhoea (n=2), melena, stro

189 ing PF-04136309 included neutropenia (n=27), febrile neutropenia (n=7), lymphopenia (n=4), diarrhoea

190 ); the most common serious adverse event was febrile neutropenia (n=9 [11%] and n=4 [4%], respectivel

191 up), neutropenia (ten [3%] vs 29 [16%]), and febrile neutropenia (one [<1%] vs seven [4%]); whereas t

192 openia (eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]), and leucopenia (six [12

193 penia (five [56%]), anaemia (two [22%]), and febrile neutropenia (two [22%]) reported in more than on

194 apy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1

195 X arms were neutropenia (19% v 10%), with 7% febrile neutropenia across arms; fatigue (13% v 11%); di

196 Prophylaxis prevented febrile neutropenia and systemic infection.

197 lly hematologic and manageable, with grade 4 febrile neutropenia in 3% of delivered courses and grade

198 hylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on

199 123 [23%] of 528 in the placebo group, with febrile neutropenia incidence of 18 [3%] vs 13 [2%]), hy

200 Febrile neutropenia incidence was low (7%).

201 elines recommend their use when the risk for febrile neutropenia is >20%.

202 le neutropenia is warranted when the risk of febrile neutropenia is approximately 20% or higher and n

203 ophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febril

204 Febrile neutropenia of grade 3 or higher was similar in

205 neutropenia, thrombocytopenia, anaemia, and febrile neutropenia or infections.

206 No cases of febrile neutropenia or neutropenia-related infections we

207 Treatment was well-tolerated; there was no febrile neutropenia or symptomatic left ventricular syst

208 combination group, the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 i

209 (14%), and diarrhea (13%); the incidence of febrile neutropenia was 7%.

210 Febrile neutropenia was observed in 4 patients.

211 nintedanib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v

212 (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [5

213 effects (mainly diarrhoea, hypertension, and febrile neutropenia).

214 t-emergent SAEs included dyspnea, pneumonia, febrile neutropenia, dehydration, and pyrexia.

215 Febrile neutropenia, diarrhea, and hematuria were more f

216 Three serious adverse events-febrile neutropenia, intestinal perforation, and cholang

217 Prophylaxis reduced the odds of febrile neutropenia, likely bacterial infection, and blo

218 tient): grade 4 atrial fibrillation, grade 4 febrile neutropenia, lung infection with grade 4 absolut

219 ramucirumab included fatigue, hypertension, febrile neutropenia, palmar-plantar erythrodysesthesia s

220 de 3) were reported in 4 patients, including febrile neutropenia, peripheral neuropathy, and hyperten

221 Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more c

222 Five (21%) of 24 had grade 3 febrile neutropenia.

223 Two patients in group B died of sepsis after febrile neutropenia.

224 nd specificity of P. falciparum detection in febrile Nigerian patients using the DLM assay, microscop

225 Of the returnees, 57 (21%) reported a febrile or diarrhoeal illness in West Africa or within 1

226 for initiating doxycycline whenever treating febrile or potentially septic patients from tribal lands

227 have a rash (P < .001) and less likely to be febrile (P < .05) or require hospitalization (P < .001).

228 UMT sensitivity among febrile patients (for whom the test was indicated) was 8

229 evant event, as centrosomes in leukocytes of febrile patients are disrupted.

230 re defined by positive RDT and controls were febrile patients from the same clinic with a negative RD

231 anda, CHWs were trained to assess and manage febrile patients in keeping with Integrated Management o

232 y aimed to measure the prevalence of ZIKV in febrile patients in Senegal and Nigeria in samples colle

233 In this case-control study, we enrolled febrile patients presenting to outpatient departments at

234 considered in the differential diagnosis of febrile patients with SFTS-like illness in endemic areas

235 ween patients with acute CHIKV-infection and febrile patients without CHIKV were compared and examine

236 y collected specimens for blood culture from febrile patients, and cerebrospinal fluid from patients

237 aria cases or sub-optimal case management of febrile patients.

238 lates were cultured from the blood of 13 431 febrile patients.

239 iagnosis of Plasmodium falciparum malaria in febrile patients.

240 e time-points, apparent already in the early febrile phase (1.29 vs 1.75; P = .012).

241 bilitating disease characterized by an acute febrile phase and chronic joint pain.

242 fused vessels and mean flow index during the febrile phase of dengue compared with follow-up, and wer

243 ENV viremia and appearance of IgM during the febrile phase of dengue provides the framework for dengu

244 Over the 10-day period of the febrile phase of dengue, the cumulative effect of using

245 response whereas normothermia and especially febrile range temperature enhance the anti-inflammatory

246 Furthermore, febrile range temperatures should be investigated as a m

247 hat hypothermic patients should be warmed to febrile range temperatures.

248 spersed from biofilms after exposure to IAV, febrile-range temperature, or ATP, and planktonic cells

249 ere judged to be related to vaccination (one febrile reaction and one anaphylaxis) and one possibly r

250 -triggered anaphylaxis, acute cardiovascular/febrile reactions).

251 inate between anaphylaxis and cardiovascular/febrile reactions, ROC curve analysis revealed a reasona

252 e the 1960s in association with outbreaks of febrile respiratory illness (FRI) in military boot camps

253 In a previous study of acute febrile respiratory illness in Bangladesh, we tested pai

254 testing were collected during maternal acute febrile respiratory infections, and from infants with an

255 We conclude that the febrile response is dependent on local release of PGE2 o

256 These data imply that the febrile response is dependent on the local release of PG

257 o identify novel genomic determinants of the febrile response to experimental endotoxemia.

258 p11.2 significantly associated with the peak febrile response to LPS (top single nucleotide polymorph

259 oradrenaline thermogenesis, but an increased febrile response to LPS.

260 hermoregulatory neurons, is critical for the febrile response to peripheral inflammation.

261 only weakly related to the magnitude of the febrile response, whereas the PGE2 synthesizing capacity

262 y reducing it in the region critical for the febrile response.

263 PGE2 level in the brain do not influence the febrile response.

264 ralized PGE2 production in the brain for the febrile response.

265 ines and attenuated systemic circulatory and febrile responses, likely reflecting decreased systemic

266 tinct acute encephalopathy syndromes, simple febrile seizures (14), other seizures (16), acute ataxia

267 pilepsy was lower in patients with prolonged febrile seizures (14.3%, 6.3-29.4) and survivors of acut

268 ts from an epilepsy GWAS meta-analysis and a febrile seizures (FS) GWAS are significantly more enrich

269 lenges due to a recognized increased risk of febrile seizures (FSs) when used as the first dose in th

270 a subset of children experiencing prolonged febrile seizures (FSs), the most common type of childhoo

271 tinct acute encephalopathy syndromes, simple febrile seizures (n = 14), other seizures (n = 16), acut

272 s in GABRG2 have been associated with simple febrile seizures and with genetic epilepsy syndromes, in

273 Febrile seizures are the most common seizure disorder in

274 articipant (2.9%, 0.5-14.5) in the prolonged febrile seizures group developed temporal lobe epilepsy

275 crocephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypi

276 Febrile seizures occurred after dose 1 of MMR vaccine at

277 identified, results in genetic epilepsy with febrile seizures plus (GEFS+).

278 enetic disorder termed "Genetic Epilepsy and Febrile Seizures Plus" (GEFS(+)).

279 absence epilepsy, generalized epilepsy with febrile seizures plus, and Dravet syndrome or severe myo

280 l gene SCN1B linked to genetic epilepsy with febrile seizures plus.

281 MMR-related febrile seizures, children with febrile seizures unrelated to vaccination and controls w

282 ayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, spastic, and/or stif

283 on scans comparing children with MMR-related febrile seizures, children with febrile seizures unrelat

284 drawal, age at onset of epilepsy, history of febrile seizures, number of seizures before remission, a

285 ia-induced convulsions, a model of pediatric febrile seizures.

286 in a 5year-old with refractory epilepsy post-febrile seizures.

287 vaccination and controls with no history of febrile seizures.

288 itive problems in individuals suffering long febrile seizures.

289 le rats following experimental prolonged FS (febrile status epilepticus; eFSE).

290 parasite of the phylum Apicomplexa, causes a febrile syndrome similar to malaria(2).

291 with VSVDeltaG-ZEBOV induced a self-limited febrile syndrome that was associated with transient dete

292 with typhoidal Salmonella serovars causes a febrile systemic disease, termed enteric fever.

293 SP90's buffering capacity with inhibitors or febrile temperatures destabilized HSP90-buffered mutants

294 patient recuperation starting from the early febrile to the defervescence and convalescent stages of

295 Febrile travelers from countries with unique endemic pat

296 hanistically related (eg, death after single febrile, unprovoked seizures, or status epilepticus).

297 coureteric reflux in children who have had a febrile urinary tract infection be reduced, but this app

298 ue Escherichia coli strains from 10 men with febrile urinary tract infections (UTIs) and their female

299 Delay in treatment of febrile UTIs and permanent renal scarring are associated

300 The patient was febrile with tachycardia on arrival.